Fox-4 10mg
Fox-4 10mg — for in vitro laboratory research use only.
Product Overview
Fox-4 is a pharmaceutical-grade research compound supplied as a lyophilized powder. Each batch undergoes independent third-party testing with a Certificate of Analysis (COA) available on request.
Specifications
| Molar Weight | ~2957.2 g/mol (approximate, per published literature) |
| Sequence | D-retro-inverso peptide (reversed sequence, built from D-amino acids), derived from the FOXO4 forkhead domain |
| Classification | Synthetic senolytic peptide; disruptor of the FOXO4-p53 protein interaction |
| Appearance | White to off-white lyophilised powder (typical presentation) |
| Solubility | Soluble in sterile water or bacteriostatic water |
| Storage | Store lyophilised powder desiccated and protected from light at -20°C. Once reconstituted, store at 2-8°C for short-term use and avoid repeated freeze-thaw cycles. |
| Shelf Life | Refer to the specific batch's Certificate of Analysis; this is a newer, less standardised research construct relative to established peptides. |
Description & Mechanism of Action
FOXO4-DRI (marketed here as Fox 4) is a D-retro-inverso peptide — meaning its sequence is reversed and built from mirror-image D-amino acids, making it resistant to normal enzymatic degradation while retaining its binding activity. It was designed at Erasmus University Medical Center to disrupt the interaction between FOXO4 and p53 inside senescent cells. In senescent cells, FOXO4 normally sequesters p53 in the nucleus, protecting the cell from apoptosis and allowing senescent cells to persist in tissue — a driver of the "senescence-associated secretory phenotype" implicated in aging. By disrupting this FOXO4-p53 interaction, FOXO4-DRI causes p53 to relocate out of the nucleus and toward the mitochondria, triggering cell-intrinsic apoptosis selectively in senescent cells — a "senolytic" effect. In the original 2017 study, treatment restored fur density, renal function, and physical activity in aged and fast-aging mouse models. As of 2026, FOXO4-DRI remains an early-stage academic research construct with no completed human clinical trials.
Applications in Research
- Studying FOXO4-p53 protein-protein interaction disruption
- Cellular senescence and senolytic mechanism research
- Aging-biomarker and tissue-homeostasis research models
- p53/BCL-2/Caspase-3 apoptotic pathway research in senescent cells
Handling, Reconstitution & Stability
- Handle as a hygroscopic powder; open vials and weigh under dry conditions where possible
- Reconstitute with sterile water or bacteriostatic water, adding solvent slowly down the side of the vial
- Swirl gently to dissolve — avoid vigorous shaking
- Filter-sterilise (e.g. 0.22 µm) immediately before use if required by your protocol
- Aliquot reconstituted solution and store at -20°C or below; avoid repeated freeze-thaw cycles
Precautions & Notes
- This is an early-stage academic research construct; no completed human clinical trials exist as of 2026
- Experimental effects are concentration-, duration-, and model-dependent
- Include appropriate experimental controls to distinguish specific from non-specific effects
- For laboratory research use only — not for human or veterinary use
This product is supplied for in vitro research purposes only. It is not intended for human or animal administration, diagnostic use, or any other purpose. Handle in accordance with good laboratory practice guidelines.